| Advances in cancer gene therapy: tumor-targeted delivery of therapeutic pDNA, siRNA, and dsRNA nucleic acids. | |
| | |
MedLine Citation:
|
PMID: 17935282 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Nonviral gene delivery systems are attractive because of their simplicity. One component (a natural or synthetic piece of nucleic acid) or two components (lipoplexes or polyplexes consisting of nucleic acid formulated with one cationic agent) may be sufficient. The simple design however entails also their limitation - a far lower efficiency than viral vectors, and lack of targeting specificity. First versions of more sophisticated "synthetic viruses" for plasmid DNA (pDNA), small interference RNA (siRNA), and dsRNA delivery have come into existence, and encouraging therapeutic effects in mouse tumor models have been observed. The development into pre-programmed bioresponsive systems, containing targeting ligands and shielding elements, and membrane-active modules promoting intracellular release is a fundamental part of the optimization process. Generation of better defined, biocompatible polymers will be an additional key aspect for successful clinical development of anticancer nucleic acid therapies. |
| | |
Authors:
|
Ernst Wagner |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Journal of B.U.ON. : official journal of the Balkan Union of Oncology Volume: 12 Suppl 1 ISSN: 1107-0625 ISO Abbreviation: J BUON Publication Date: 2007 Sep |
Date Detail:
|
Created Date: 2007-10-15 Completed Date: 2007-11-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883428 Medline TA: J BUON Country: Greece |
Other Details:
|
Languages: eng Pagination: S77-82 Citation Subset: IM |
Affiliation:
|
Pharmaceutical Biotechnology and Center of NanoScience, Ludwig-Maximilians Universität, Munich, Germany. ernst.wagner@cup.uni-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Biocompatible Materials / chemistry Gene Expression Regulation, Neoplastic Gene Therapy / methods*, trends Gene Transfer Techniques* Humans Ligands Mice Nanotechnology Neoplasms / genetics, metabolism, therapy* Plasmids / metabolism* Polymers / chemistry RNA, Double-Stranded / metabolism* RNA, Small Interfering / metabolism* Receptors, Cell Surface / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Biocompatible Materials; 0/Ligands; 0/Polymers; 0/RNA, Double-Stranded; 0/RNA, Small Interfering; 0/Receptors, Cell Surface |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Next Document: Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endot...